On Monday, Immunocore Holdings ADR received an upgrade to its Relative Strength (RS) Rating, from 70 to 80.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History shows that the top-performing stocks often have an RS Rating of over 80 as they begin their biggest price moves.
While Immunocore Holdings ADR is not near an ideal entry right now, see if it is able to form and break out from a proper chart pattern.
The company posted 0% EPS growth in its most recent report, while sales growth came in at 36%.
The company holds the No. 50 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
